title: Efavirenz dose reduction in HIV-infected patients.
authors.forename: M
authors.initials: M
authors.lastname: Lanzafame
authors.forename: S
authors.initials: S
authors.lastname: Bonora
authors.forename: E
authors.initials: E
authors.lastname: Lattuada
authors.forename: S
authors.initials: S
authors.lastname: Vento
mesh_terms: D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D048588:Benzoxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz